Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study

Roux, Barbara; Bezin, Julien; Morival, Camille; Noïze, Pernelle; Laroche, Marie-Laure

doi:10.1080/14737167.2021.1981863

Cited by 6 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prescribed proton pump inhibitors at a maximum therapeutic dose for >8 weeks accounted for 54% of this cost; conversely, the same criterion only accounted for 4% of our total PIP cost. This is explained by differences in medication cost used and prevalence of the criterion in each study population, 3% in this study vs. 17% for Cahir et al 18 Several studies have investigated the prevalence of PIP amongst older adults, but more specifically, they have reported the prevalence of different instances of PIP based on different criteria, such as the STOPP/START criteria and PROMPT criteria when investigating middle-aged adults; a common finding being that duplicate drug classes is a highly prevalent PIP criterion in both age groups 15,[32][33][34] and likely to be a factor contributing to increasing ADE rates and hospital admissions related to PIP. Although it is important to note middleaged adults remains an understudied population; therefore, further studies analysing prevalence are needed to cement this trend with this group.…”

Section: Interpretations and Context Of Existing Literaturementioning

confidence: 71%

“…Several studies have investigated the prevalence of PIP amongst older adults, but more specifically, they have reported the prevalence of different instances of PIP based on different criteria, such as the STOPP/START criteria and PROMPT criteria when investigating middle‐aged adults; a common finding being that duplicate drug classes is a highly prevalent PIP criterion in both age groups 15,32–34 and likely to be a factor contributing to increasing ADE rates and hospital admissions related to PIP. Although it is important to note middle‐aged adults remains an understudied population; therefore, further studies analysing prevalence are needed to cement this trend with this group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost outcomes of potentially inappropriate prescribing in middle‐aged adults: A Delphi consensus and cross‐sectional study

Jayesinghe

Moriarty²,

Khatter

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

Background: Potentially inappropriate prescribing (PIP) is common in older adults and is associated with increased medication costs and costs of associated adverse drug events. PIP also affects almost 1/5 of middle-aged adults (45-64 y), as defined by the PRescribing Optimally in Middle-aged People's Treatments (PROMPT) criteria.However, there has been little research on PIP medication costs within this age group.Aims: Calculate the medication costs of PIP for middle-aged adults according to the 22 PROMPT criteria and compare with the cost of consensus-validated, evidencebased (adequate) alternative prescribing scenarios. Methods: Adequate alternatives to the 22 PROMPT criteria were created via literature review. A Delphi consensus panel of experts was recruited (n = 16), supported by a patient and public involvement group, to achieve consensus on the alternatives. A retrospective repeated cross-sectional study from 2014 to 2019 was then conducted utilising pseudonymised primary care data from Lambeth DataNet in South London (41 general practices, n = 1 185 335, using Lambeth DataNet May 2020 extract) to calculate the cost of PIP. Results: The cross-sectional study included 55 880 patients. The total PIP cost was £2.79 million, with adequate alternative prescribing costing £2.74 million (cost savings of £51 278). Duplicate drug classes was the most costly criterion for both PIP and alternative prescribing. Conclusion: This study calculated the medication costs of PIP and created alternative prescribing scenarios for the 22 PROMPT criteria. There is no substantial cost difference between adequate prescribing vs. PIP. Future studies should investigate the wider health economic costs of alternative prescribing, such as reducing hospital admissions.

show abstract

Section: Interpretations and Context Of Existing Literaturementioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

Cost outcomes of potentially inappropriate prescribing in middle‐aged adults: A Delphi consensus and cross‐sectional study

Jayesinghe

Moriarty²,

Khatter

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Attitudes and beliefs of older adults and caregivers towards deprescribing in French-speaking countries: a multicenter cross-sectional study

Roux

Rakheja

Sirois

et al. 2022

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

Successful deprescribing requires understanding the attitudes of older adults and caregivers towards this process. This study aimed to capture these attitudes in four French-speaking countries, and to investigate associated factors. MethodsA multicenter cross-sectional study was conducted by administrating the French version of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire in Belgium, Canada, France and Switzerland. Community-dwelling or nursing home older adults ≥ 65 years taking ≥ 1 prescribed medications, and caregivers of older adults with similar characteristics were included. Multivariate logistic regressions were carried out to examine factors associated with willingness to deprescribe. ResultsA total of 367 older adults (79.3 ± 8.7 years, 63% community-dwelling, 54% ≥5 medications) and 255 unrelated caregivers (64.4 ± 12.6 years) of care recipients (83.4 ± 7.9 years, 52% community-dwelling, 69% ≥5 medications) answered the questionnaire. Among them, 87.5% older adults and 75.6% caregivers would be willing to stop medications if the physician said it was possible. Reluctance to stop a medication taken for a long time was expressed by 46% of both older adults and caregivers. A low score for the factor "concerns about stopping" [older adults: aOR: 0.

show abstract

Drugs and the elderly: A complex interaction

2023

View full text Add to dashboard Cite

Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study

Cited by 6 publications

References 51 publications

Cost outcomes of potentially inappropriate prescribing in middle‐aged adults: A Delphi consensus and cross‐sectional study

Cost outcomes of potentially inappropriate prescribing in middle‐aged adults: A Delphi consensus and cross‐sectional study

Attitudes and beliefs of older adults and caregivers towards deprescribing in French-speaking countries: a multicenter cross-sectional study

Drugs and the elderly: A complex interaction

Contact Info

Product

Resources

About